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Background: Retropubic radical prostatectomy with intentional wide resection (RRP-WR), which enables clear
location of the prostate apex and the performance of posterolateral wider resection to remove extraprostatic
extension, was introduced to our institutions. The aim of this study is to assess the feasibility and the efficacy of
RRP-WR as a surgical intervention for locally confined prostate cancer.
Methods: A total of 90 Japanese patients with pathologically proven and clinically locally confined hormone-naïve
prostate cancer were treated through RRP-WR, and the surgical morbidity was assessed. The patients were observed
without immediate treatment until biochemical recurrence (BCR).
Results: The surgical morbidities were comparable to conventional procedures. No positive surgical margin (pSM)
was pathologically identified in pT2 cases from prostatectomy specimens. It was identified in only 14.3% of pT3a
cases, 36.4% of pT3b cases and 100% of pT4 cases. No apical pSM was found except for one of the pT4 cases in the
levator ani muscle. PSA was at an undetectable level in 80.0% of all cases, 90.0% of pT2 cases, and 67.5% of pT3
and pT4 cases after surgery. The BCR-free survival rate in all cases was 82.4% and that of high-risk cases without
pSM was 76.9% at a median follow-up of 19.3 months (3.3 to 59.2).
Conclusions: RRP-WR is feasible and effective in removing organ-confined prostate cancer as well as extraprostatic
extension without pSM. Thus, it is worthwhile to evaluate if this procedure improves the clinical outcome of locally
confined prostate cancer including high-risk conditions treated by surgical intervention.
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The advent of prostate-specific antigen (PSA) screening
has resulted in an overall reduction of prostate cancer. It
has also been found that the majority of prostate cancer
cases are diagnosed in individuals over 60 years old and
grow slowly, meaning that they are not lethal within the
remaining life span. However, there are still cases in* Correspondence: e-okajima@nara-jadecom.jp
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reproduction in any medium, provided the orwhich clinically locally confined but high-risk prostate
cancer progresses and causes metastasis and cancer
death [1]. The benefits of the various treatment options
available for those with high-risk disease remain un-
proven [2]. Even though radical prostatectomy results in
excellent prognosis for low-risk prostate cancer [3], for
high-risk cases, the guidelines of the European Asso-
ciation of Urology (EAU) [4] and the National Compre-
hensive Cancer Network (NCCN) [5] recommend the
procedure as an optional therapy.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Patient characteristics
All 90 cases High-risk
cases (32)
Age (years) 68.1 (54 – 78) 68.1 (57 – 78)
Initial PSA (ng/ml) 11.39 (3.12 – 33.93) 17.10 (4.72 – 33.93)
Gleason score in biopsy
specimens
7.0 (6 – 9) 7.5 (6 – 9)
Maximum cancer occupation
per a biopsy core (%)
42.4 (5 – 100) 52.4 (5 – 100)
Gleason score in
prostatectomy specimens
7.1 (6 – 9) 7.5 (6 – 9)
Follow-up period after
surgery (months)
23.0 (3.3 – 59.2) 17.4 (3.3 – 56.1)
Table 2 Number of cases with positive surgical margin
according to preoperative clinical and pathological
T category
cT1c cT2a cT2b cT3a
pT2a 12 3 0 0 15
pT2b 8 1 2 0 11
pT2c 18 2 0 4 24
pT3a 16 (pSM*: 2) 6 (pSM*: 2) 0 6 28 (pSM*: 4)
pT3b 2 4 (pSM*: 2) 1 4 (pSM*: 2) 11 (pSM*: 4)
pT4 0 1 (pSM*: 1) 0 0 1 (pSM*: 1)
56 (pSM*: 2) 17 (pSM*: 5) 3 14 (pSM*: 2) 90 (pSM*: 9)
pSM: positive surgical margin.
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prostate cancer is complete prostate extirpation, and it is
well known that curable resection without a positive sur-
gical margin (pSM) is essential for positive results [6].
Since high-risk locally confined prostate cancer often
demonstrates extraprostatic extension (EPE) in prosta-
tectomy specimens exhibiting pSM, better prognostic
results can be expected from a wider resection than that
of the current operative procedure. Since more than half
of pSM is found in the apex of the prostate compared to
its other parts [7], it is also important to clearly locate
the prostate apex.
Fujimoto reported on a method of intentional wide re-
section for the prostate that enables clear location of the
prostate apex and the performance of posterolateral
wider resection to remove EPE in cases without pSM
[8-10].
In this study, to improve the control of locally confined
prostate cancer, we evaluated retropubic radical prosta-
tectomy with intentional wide resection (RRP-WR) – a
procedure that can not only remove some of the EPE of
the cancer but can also reduce the apical pSM – for lo-
cally confined prostate cancer, including high-risk cases.
Methods
We diagnosed prostate cancer pathologically using more
than eight biopsy specimens per individual and ascer-
tained the stage of locally confined disease through bone
scanning and computed tomography and/or magnetic
resonance imaging. After excluding cases with cT3b
(seminal vesicle involvement) and worse (cT4) local-
stage development through imaging study (because
Fujimoto et al. reported a poor survival benefit from
RRP-WR even with neoadjuvant androgen-deprivation
therapy [10]), we gave informed consent in terms of
treatment for locally confined prostate cancer, including
active surveillance, brachytherapy, external beam ra-
diation, intensity modulated radiation therapy, and ra-
dical prostatectomy with or without nerve preservation.
From January 2007 to December 2011, 90 prostate can-
cer patients (cT1c, cT2 or cT3a) who accepted radical
prostatectomy were treated with RRP-WR without any
prior therapy, and we observed them without immediate
post-surgical adjuvant therapy. Three patients had unila-
teral neurovascular bundle preservation and contralateral
wide resection. The clinicopathological characteristics of
all 90 cases before surgery are shown in Table 1.
High-risk cases were defined as those with a Gleason
score of 8 to 10, an initial PSA of more than 20 ng/ml
or a preoperative local stage of cT3a according to the
criteria of NCCN [5,11]. There were 32 cases of high-
risk prostate cancer.
After lymph node dissection of the bilateral obturator
area, we performed intended wide resection according tothe method outlined by Fujimoto et al. [8-10]. Briefly,
after incision of the endopelvic fascia along the pelvic
wall, we identified the neurovascular bundle before per-
forming incision of the lateral pelvic fascia posterolate-
rally from the neurovascular bundle. We then separated
the mesorectal fat from the muscle layer of the rectum
until it could no longer be easily separated to the point
at which the rectourethral muscle was reached or until
the proximal region of either the vas deferens or the
peritoneum of the Douglas fossa was identified. Knowing
the position of the external rectal sphincter clarifies the
location of the urethral sphincter.
A single pathologist (K.S.) evaluated the degree of ma-
lignancy in the biopsy and prostatectomy specimens
according to the Gleason grading system [12] and the
stage based on the 2004 TNM classification [13]. The
prostatectomy specimens were fixed in 10% buffered for-
malin and sectioned into 3-mm slices in the plane per-
pendicular to the long axis of the gland from the apex to
the tip of the seminal vesicles, followed by hematoxylin
and eosin staining and determination of EPE. Eighteen
cases (32.1%) of 56 cT1c cases and 11 cases (64.7%) of
17 cT2a cases were found pT3 or pT4 (Table 2).
We analyzed factors associated with surgical morbid-
ity, such as operative time, blood loss during the ope-
ration, number of days with a urethral catheter after
Table 3 Adverse events
Event Number of cases
Lymph leakage 3
Stricture at urethral anastomosis 3
Wound infection 2
Bleeding 2 days after operation 1
Pulmonary infarction 1
Hydronephrosis 1
Incontinence requiring more than 1 pad a day* 3
*Among 80 cases, with follow-up lasting 6 months.
Okajima et al. World Journal of Surgical Oncology 2012, 10:249 Page 3 of 7
http://www.wjso.com/content/10/1/249surgery, number of days in the hospital after surgery and
any adverse events.
After prostatectomy, we followed up with a PSA assay
every 3 months for the first 2 years, every 6 months for
the next 3 years, and yearly thereafter. We also added
PSA measurement if unfavorable PSA elevation was
observed. The mean and median follow-up values were
23.2 and 19.3 months (range: 3.3 – 59.2), respectively.
Even though the efficacy of cancer treatment should
be evaluated by cause-specific survival, we used the
achievement of undetectable PSA, which has been
reported as a significant predictor of biochemical recur-
rence (BCR) in pT3 cases after surgery by multivariate
analysis [14], and BCF-free survival as surrogate end-
points because the natural history of prostate cancer is
very long and PSA is extremely sensitive. The date of
BCR was defined as the time at which the serum PSA
level exceeded 0.2 ng/ml after surgery. The patients
received no adjuvant therapy immediately after surgery,
and they were subsequently treated with radiation ther-
apy and/or androgen deprivation therapy only after BCR
as described above. Four cases with lymph node metas-
tasis were found among the 90 cases included.
We used the Kaplan-Meier survival estimation curve
and the log rank method for univariate analysis. As the
number of cases was relatively small, it was not possible
to perform multivariate analysis to find factors for pre-
dicting the clinical outcome of RRP-WR.
Results
Morbidity with RRP-WR
The mean and median operative times were 307 min
and 304 min, respectively. It took over 5 h to perform
the operation for the first year, as it was a newly intro-
duced procedure. After around 20 cases, our technique
had advanced to enable completion within 4 h.
The mean and median blood loss amounts during sur-
gery were 998 ml and 858 ml, respectively. Auto-
transfusion covered the bleeding, and no allo-transfusion
was given to any of the patients. As the operating time
decreased, blood loss decreased.
In half the cases the urethral catheter was removed
following initial cystography 4 or 5 days after surgery.
The mean and median numbers of days with catheter
presence were 10.2 and 8, respectively.
The number of days in the hospital after surgery
depended on the progress of surface wound healing ra-
ther than on healing related to urethral anastomosis.
Half the patients left the hospital less than 9 days after
surgery. The mean and median numbers of days in the
hospital after surgery were 11.3 and 8, respectively. In-
continence requiring more than two pads a day was
observed 3 months after surgery in six cases (6.5%).
After 6 months, incontinence requiring more than onepad a day was seen in only three cases (3.8% of 80 cases,
with follow-up lasting more than 6 months) with early
BCR.
Intentional wide resection aimed to reduce the pSM
rate, which by its nature cannot preclude an outcome of
erectile dysfunction. In this work, we did not assess
erectile dysfunction because it is obvious that patients
will suffer loss of erectile functionality when given
intentional wide resection.
Three had sustained lymph leakage, three developed
stricture at urethral anastomosis, two had a wound in-
fection, one had bleeding 2 days after surgery, one had a
minor pulmonary infarction, and one patient with a past
history of urolithiasis had unilateral hydronephrosis of
unknown origin that improved spontaneously (Table 3).Pathological results of 90 cases from prostatectomy
specimens
Eighty of all 90 cases demonstrated perineural invasion.
Gleason scores of 7 were found in 74 cases (82.2%), and
scores of 9 were found in 6 cases (6.7%). Two patients
with pT2c, one with pT3a and one with pT3b had lymph
node metastasis. One patient was diagnosed with pT4
with levator ani invasion.
In terms of the association of preoperative clinical
local staging with pathological results in prostatectomy
specimens, we adopted cases in this study to the Japan
PC table [15]: a preoperative nomogram for Japanese
patients with locally confined prostate cancer. There
were 58 cases clinically diagnosed as organ-confined (T1
and T2) and low risk by NCCN criteria. According to
the Japan PC table, the probability of EPE for 34 of 58
cases was less than 25%, and 9 of these 34 (26.5%)
patients were found to have EPE by prostatectomy speci-
mens. And 24 of 58 patients were predicted to have a
more than 25% probability of EPE, and 13 of these 24
(54.2%) patients were found to have EPE. Eighteen cases
were clinically diagnosed as organ-confined (T1 and T2)
and high risk by the NCCN criteria. The probability of
EPE for 15 of 18 (83.3%) cases was over 25%, the mean
probability of EPE for these 18 cases was 41.6%, and 7 of
Figure 1 BCR-free survival rate in cases with and without pSM
from prostatectomy specimens. BCF-free survival rates in cases
with and without pSM were shown to be 37.5% and 89.1% at
2 years estimated to achieve BCR-free survival, respectively.
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tomy specimens.
No pSM was found in 50 cases of pT2, and only 4
cases (14.3%) with pSM were found in 28 cases of pT3a.
Even among 11 cases of pT3b, 7 were removed without
pSM.
Preliminary clinical outcome of 90 cases by PSA
PSA was reduced to undetectable levels in 72 (80.0%) of
90 cases. BCR was found in 15 cases during the follow-
up period (Table 4).
BCR-free survival at a median follow-up of 19.3
months (3.3-59.2) was estimated at 82.4% using the
Kaplan-Meier survival estimation curve, with 23.0
months (range: 3.3 – 59.2) of mean follow-up for the 90
patients.
Although we did not compare inter-group difference
statistically because the follow-up period is too short for
prostate cancer, BCR-free survival rates in cases with
and without pSM were demonstrated as being 37.5%
and 89.1% of those that were estimated at 2 years to
achieve BCR-free survival, respectively (Figure 1). Fur-
thermore, among 32 high-risk cases, BCR-free survival
rates in patients with and without pSM were demon-
strated as being 40.0% and 76.9% of those that were esti-
mated at 2 years to achieve BCR-free survival,
respectively (Figure 2).
When focusing on cases of pT3 and pT4, there were
40 cases among the 90 patients. BCR-free survival of
these 40 cases was estimated to be 74.3% at 2 years after
surgery. BCR-free survival rates in cases with and with-
out pSM were 42.9% and 84.5% of those that were esti-
mated at 3 years to achieve BCR-free survival,
respectively (Figure 3).
Discussion
To improve prostate cancer control, we performed RRP-
WR for 90 cases of preoperative locally confined pros-
tate cancer, and we evaluated the surgical outcome by
morbidity and curability with surgical margin status
pathologically. We tried to demonstrate preliminaryTable 4 pSM and PSA decline according to pathological T
category
Pathological T pSM* (%) Undetectable PSA (%)
T2a 15 0 (0) 15 (100)
T2b 11 0 (0) 8 (72.7)
T2c 24 0 (0) 22 (91.7)
T3a 28 4 (17.9) 19 (67.9)
T3b 11 4 (36.4) 8 (72.7)
T4 1 1 (100) 0 (0)
Total 90 9 (10) 72 (80)
pSM: positive surgical margin.clinical outcomes by achievement of undetectable PSA
and BCR without immediate adjuvant therapy after
surgery.
Half the procedures took more than 4 h to complete,
partly because of the time taken for lymph node dissec-
tion. We routinely performed obturator lymph node dis-
section, and internal iliac lymph node dissection was
also implemented for high-risk cases by NCCN classifi-
cation. Lymph node dissection in radical prostatectomy
is mainly for the purpose of staging, but for advanced
cases it may be therapeutic [16]. Only four instances of
lymph node metastasis were found in this series of cases,
and three of these four patients achieved undetectable
postoperative PSA, two without BCR at 3 and 30Figure 2 Estimated BCR-free survival rate difference in cases
with and without pSM among 18 high-risk cases treated with
RRP-WR alone among 32 high-risk cases; BCR-free survival rates
in cases with and without pSM was shown as being 40.0% and
76.9% at 3 years estimated to achieve BCR-free survival,
respectively.
Figure 3 Estimated BCR-free survival rate in cases with and
without pSM among 40 pT3 and pT4 cases treated with RRP-WR
alone. BCR-free survival rates in cases with and without pSM were
shown as being 42.9% and 84.5% at 3 years estimated to achieve
BCF-free survival, respectively.
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at 25 and 47 months after surgery.
Although blood loss was not trivially small, it could be
deemed acceptable because no allo-transfusion was
required and the loss level of less than 1,000 ml is lower
than or comparable to the values of 800 to 1,650 ml
noted in previous reports [17,18]. The number of days
with urethral catheter presence after surgery and the
number of days spent in the hospital after surgery were
also not longer than those in previous reports. It takes
time to recover from incontinence (6.5% required more
than two pads a day at 3 months after surgery), but after
6 months, incontinence with more than one pad a day
was seen only in three cases with early BCR. Another re-
port on this procedure also mentioned that a period of 6
months is required to recover continence [9]. Thus, the
procedure can be seen as feasible.
Kupelian et al. reported that intracapsular pSM for
organ-confined (pT2) disease from radical prostatectomy
with inadvertent incision through the capsule in a tumor
was 18% [19]. Kordon et al. also reported that among
1,378 cases of pT2, 16.9% showed pSM [20]. Even with
minor modification to reduce apical pSM, pSM in
organ-confined disease could not be eliminated com-
pletely [21]. In this study, we achieved resection without
pSM for all pT2 patients through RRP-WR, although the
number of cases was small. Locating the rectourethral
muscle enabled clarification not only of the urethral
sphincter’s location, but also that of the prostate apex.
This is a major advantage of the procedure for resection
without pSM. However, most cases with organ-confined
disease are in a good risk group for which more than 10
years of survival can be expected with any definitive
monotherapy [1,22]. In terms of control for organ-confined (pT2) prostate cancer, we consider that this
procedure would be as successful as the regular RRP
procedure, although more would cause erectile dysfunc-
tion, which was not analyzed in this work.
For patients with pT3 and pT4, curative resection was
achieved without pSM at a rate of 77.5%. Inagaki et al.
reported a no-pSM rate of 38.7% for 106 cases of pT3a
and pT3b that had been diagnosed as cT1 and cT2 pre-
operatively [14], and Kordon et al. also reported that the
incidence of no pSM in 288 pT3a cases was 52.1% [20],
which is much lower than the respective 82.1% and
85.7% values seen in our series.
This increase in the ratio of resection without pSM for
cases with pT3 and pT4 seems to have contributed to
better cancer control. In this series, pT3 and pT4 cases
without pSM demonstrated an 84.5% BCR-free survival
rate 2 years after surgery, which is much higher than the
37.5% value seen for cases with pSM. Since the follow-
up period is short, we also evaluated achievement of un-
detectable PSA after surgery, which has been reported as
a significant predictor of BCR in pT3 cases after surgery
by multivariate analysis [14], and found a figure of 92.5%
for cases with pT3 and pT4. Recently, Preston et al.
reported the prognostic significance of curative resection
for cases with non organ-confined disease by radical
prostatectomy [23]. They demonstrated that cases with
completely resected extraprostatic disease had a higher
probability of BCR-free survival (86% at 5 years after
surgery) than those with capsular incision into tumors of
organ-confined disease did (77% at 5 years after surgery).
Thus, with RRP-WR we can expect better prognosis of
locally confined prostate cancer with EPE treated surgi-
cally than previous reports indicate, although it is neces-
sary to confirm the long-term results for a large number
of cases before making a firm conclusion.
In terms of the indication of this procedure compared
to regular RRP, we consider that locally confined but
non-organ-confined or no seminal vesicle involvement
(pT3a) cases may deserve the advantage of the proce-
dure as opposed to regular RRP. As mentioned above,
for good risk cases [such as those with an initial PSA of
less than 10, a Gleason score of less than 7 or organ-
confinement (pT2)], the regular and well-established
procedure of radical prostatectomy is good enough to
achieve a survival period of 10 years. The authors
demonstrated 10-year cause-specific survival greater
than 95% for pT2 cases treated by radical prostatectomy
[24]. Erectile dysfunction, which cannot be avoided be-
cause of the nature of wide resection, is one disadvan-
tage of this procedure, although we did not assess
erectile dysfunction in this work. Thus, for pT2 cases,
nerve-sparing prostatectomy results in a better risk/
benefit ratio. Cases of pT3b (seminal vesicle invasion)
and pT4 (direct invasion to surrounding organ or
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pSM from pathological evaluation of prostatectomy spe-
cimens [10]. As preoperative evaluation cannot ascer-
tain beyond doubt whether the disease is pT3a, such
cases cannot be chosen before the operation. Without
pathological evaluation of the entire prostate after re-
moval by radical prostatectomy, it is also not possible to
tell at the preoperative stage whether the disease is
organ-confined.
In this series, concerning the T category, we found that
most of the cases (62 of 90 cases) were underestimated
preoperatively compared to the results from the prosta-
tectomy specimens. We reevaluate the cases of this
study using the Japan PC table [15] to find the reason
for this discrepancy. As the Japan PC table and NCCN
risk criteria seem to correlate with each other in this
series, our results are also in line with the prediction of
the table. Thus, we confirmed that simple clinical T ca-
tegory cannot tell the pathological results in prostatec-
tomy specimens and that the Japan PC Table is useful to
determine the probability of EPE of clinically organ-
confined disease.
Also in our series, 30 (40.5%) of 74 cT1c and cT2 cases
were pT3 and worse pathologically. Among these 30
preoperatively underestimated cases, successful removal
was achieved in 23 (76.7%) by RRP-WR. More than half
of the cases in this series did not require RRP-WR to
achieve resection without pSM, but 23 of 74 cases
(31.1%) with cT1c and cT2 would have failed if the pro-
cedure had not been performed. Although it is difficult
to expect a good prognosis for cases with pT3b and pT4
from radical prostatectomy alone, even without pSM
[10], 18 of 22 patients with pT3a that had been diag-
nosed as cT1c or cT2 preoperatively deserved the advan-
tage of RRP-WR because prostate and prostate cancer
removal was achieved without pSM.
Conclusions
To improve prostate cancer control, we performed RRP-
WR for 90 cases of preoperative locally confined pros-
tate cancer, and we evaluated the surgical outcome by
morbidity and curability with surgical margin status
pathologically. We tried to demonstrate preliminary cli-
nical outcomes by achievement of undetectable PSA and
BCR, despite the short follow-up period, without imme-
diate adjuvant therapy after surgery.
RRP-WR was as feasible as the conventional proce-
dure, and that surgical outcome, in terms of pSM, was
equal or superior to those cases with pT2 and far super-
ior to those cases with pT3 in previous reports. The pre-
liminary clinical outcomes in terms of postoperative
undetectable PSA and BCR-free survival without adju-
vant therapy encouraged us to continue this procedure
for cases preoperatively diagnosed as cT1-2, especiallyfor the cases with high probability of EPE according to
the Japan PC Table and cT3a. It is necessary to confirm
the long-term results to demonstrate the advantage of
this procedure.
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